CIP
SAGE

Chartwell Investment Partners’s Sage Therapeutics SAGE Stock Holding History

Chartwell Investment Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,908
Closed -$643K – 424
2019
Q4 		$643K Buy
8,908
+4,045
+83% +$498K 0.02% 377
2019
Q3 		$682K Sell
4,863
-78
-2% -$13K 0.02% 377
2019
Q2 		$905K Sell
4,941
-16,934
-77% -$2.89M 0.03% 384
2019
Q1 		$3.48M Buy
21,875
+384
+2% +$55.6K 0.11% 252
2018
Q4 		$2.06M Sell
21,491
-11,951
-36% -$1.37M 0.07% 329
2018
Q3 		$4.72M Buy
33,442
+8,504
+34% +$1.31M 0.14% 220
2018
Q2 		$3.9M Sell
24,938
-3,495
-12% -$549K 0.12% 239
2018
Q1 		$4.58M Sell
28,433
-370
-1% -$62.8K 0.16% 201
2017
Q4 		$4.74M Buy
28,803
+6,839
+31% +$663K 0.16% 206
2017
Q3 		$1.37M Sell
21,964
-19,482
-47% -$1.53M 0.05% 359
2017
Q2 		$3.3M Buy
41,446
+14,575
+54% +$1.05M 0.12% 225
2017
Q1 		$1.91M Sell
26,871
-34,271
-56% -$2.01M 0.07% 294
2016
Q4 		$3.12M Buy
+61,142
New +$2.88M 0.11% 269

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Chartwell Investment Partners's SAGE Position: Q1 2020 in Review

Chartwell Investment Partners sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 8,908 shares — an estimated $643K sold.

Chartwell Investment Partners first reported a position in SAGE in Q4 2016 and held it in 13 quarters. The position peaked at $4.74M in Q4 2017. 230 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • Chartwell Investment Partners reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Chartwell Investment Partners sold 8,908 Sage Therapeutics shares in Q1 2020, an estimated $643K.
  • Chartwell Investment Partners first reported a position in Sage Therapeutics in Q4 2016 and held it in 13 quarters.
  • Chartwell Investment Partners's Sage Therapeutics position peaked at $4.74M in Q4 2017.
  • 230 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Chartwell Investment Partners's 13F filing for Q1 2020, filed 30 Apr 2020.